Building the future of pharma manufacturing
We’re reimagining how pharma companies, CDMOs, and CROs collaborate to move products from lab to market faster and with greater certainty.
Streamlining the beginning of every tech transfer to save time, reduce errors, and protect the bottom line.
The early stages of a pharmaceutical technology transfer are where most costly mistakes are made. Incomplete documentation, misaligned specifications, unclear capability requirements, and fragmented communication between sending and receiving sites create a cascade of problems that compound over months and years. By the time these gaps surface during scale-up or validation, the cost to fix them has multiplied tenfold.
Our mission at TransferPilot is to fundamentally streamline this critical beginning phase. We believe that by applying AI-powered document intelligence, automated gap analysis, and real-time collaboration tools to the earliest stages of the transfer process, we can catch the issues that traditionally go unnoticed until they become expensive problems. When teams have complete visibility from day one, when every specification is automatically cross-referenced, and when every stakeholder is aligned on the same source of truth, the entire transfer runs faster, cleaner, and with far fewer surprises.
The result is tangible: shorter timelines that get products to patients sooner, fewer errors that would otherwise trigger rework and regulatory setbacks, and significant cost savings that protect both the companies executing the transfer and the patients who depend on their success. We’re not just building software. We’re building the infrastructure that makes pharma tech transfer work the way it should have all along.
Why We Built This
This isn’t an abstract industry problem for us. From personal experience, we’ve watched millions of dollars get lost because of improper tech transfers from clients to CDMOs. We’ve seen the trickle down effect firsthand. What starts as a misaligned spec or an incomplete document turns into months of rework, blown budgets, broken partnerships, and real people losing their jobs.
It may not seem like it on the surface, but a bad tech transfer creates a chain reaction. The CDMO loses trust in the client. The client loses confidence in the timeline. Investors lose patience. Teams get restructured. People who had nothing to do with the original problem end up paying the price.
The worst part is that most of these failures were preventable. Issues that could have been flagged and mitigated early in the pipeline become serious problems down the line, when the cost to fix them is 10x higher and the damage to the relationship is already done. That’s why we built TransferPilot.
Millions Lost
We’ve watched millions disappear from improper tech transfers between clients and CDMOs. A single transfer costs over $5M. When things go wrong, rework and delays multiply that number fast. What was supposed to be a routine handoff becomes the most expensive mistake of the year.
Trust Destroyed
Bad transfers don’t just cost money. They break the relationship between partners. Client trust that took years to build gets killed in weeks. Deals that entire teams depended on collapse. And once that trust is gone, it rarely comes back.
People Lose Jobs
When transfers fail and costs spiral, companies cut headcount. Real people pay the price for problems that were completely preventable with better tools, earlier visibility in the pipeline, and proper documentation from day one.
Preventable Problems
The issues that blow up late in the process almost always had warning signs early on. A missing capability assessment. An incomplete batch record. A spec that nobody reviewed. These are solvable problems if you catch them early enough. That’s what TransferPilot does.
Our Team
Patrick Fulton Steele
With a background in science and over a decade in biotechnology, Patrick connects deep technical expertise with modern AI solutions. He specializes in AI strategy, product development, and building tools that solve real problems in pharma. His experience spans project management, data analysis, process automation, and technology transfer. He co-founded Microbiocol AI to help businesses adopt AI in a way that’s practical and people-first.
Dr. Stephany Taylor
Stephany holds a PhD in Energy and Environmental Systems and brings a rare combination of scientific depth, technical skill, and entrepreneurial drive. Trained in AI and machine learning with hands-on expertise in Python, data mining, and ML algorithms, she understands how to translate complex data and systems into real-world impact. She co-founded Microbiocol AI to bring rigorous, science-backed thinking to every solution the company builds.
What Drives Us
Precision
Pharma doesn’t tolerate approximation. We build to regulatory standards, not marketing promises.
Transparency
Real-time visibility into every transfer. No hidden gaps. No surprises.
Collaboration
Tech transfer succeeds when everyone is aligned. We unify teams, not fragment them.
Speed
Every day of delay costs real money. We obsess over efficiency without compromising safety.